hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06387134 id: TCM for early-stage LUAD briefTitle: Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment overallStatus: RECRUITING date: 2022-12-01 date: 2025-01-01 date: 2025-05-31 date: 2024-04-26 date: 2024-04-26 name: Henan University of Traditional Chinese Medicine class: OTHER briefSummary: This study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic Lifei Xiaoji Wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional Chinese medicine conditions: Early Stage Lung Adenocarcinoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Lifei Xiaoji Wan name: Conventional treatment with Western medicine measure: Lung Cancer Quality of Life Scale (FACT-L) measure: TCM symptoms and syndromes measure: Evaluation of tumor efficacy using RECIST criteria to measure changes in tumor body measure: Tumor markers：CEA measure: Tumor markers：CA211 measure: Tumor markers：squamous cell carcinoma antigen measure: Complete blood count: white blood cells measure: Complete blood count: haemoglobin measure: Complete blood count: Platelet measure: Liver function tests: ALT measure: Liver function tests: AST measure: Renal function tests: BUN measure: Renal function tests: Cr sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mingli Zhao status: RECRUITING city: Zhengzhou country: China name: Mingli Zhao, MD role: CONTACT phone: 0371-66246152 email: 13937159120@163.com lat: 34.75778 lon: 113.64861 hasResults: False
nctId: NCT06387121 id: IIT2023060-EC-1 briefTitle: Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-12-01 date: 2028-12-31 date: 2024-04-26 date: 2024-04-26 name: Institute of Hematology & Blood Diseases Hospital, China class: OTHER briefSummary: In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL), despite the achievements of chemotherapy and immunotherapy, the therapeutic outcomes are unsatisfactory in elderly or unfit patients. In recent years, tumor immunotherapy has demonstrated a high safety and efficacy profile in refractory Ph- B-ALL patients. These findings suggest that the advancement of immunotherapy application may be an important approach to improve patient survival. In this study, we propose a treatment approach that combines immuno-targeted drugs with low-dose chemotherapy for newly diagnosed elderly or unfit patients with Ph- B-ALL, aiming to enhance the measurable residual disease (MRD)-negative complete remission (CR) rate measured through flow cytometry following induction therapy, reduce the risk of relapse, and ultimately improve patients' overall survival. conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 53 type: ESTIMATED name: Vincristine name: Cyclophosphamide name: Dexamethasone name: Venetoclax name: Inotuzumab ozogamicin name: Blinatumomab name: 6-mercaptopurine name: Methotrexate name: Cytarabine name: Prednisone measure: MRD-negative complete remission rate measured by flow cytometry. measure: Complete remission (CR) rate measure: Overall survival (OS) measure: Relapse free survival (RFS) measure: Disease-free Survival (DFS) measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387108 id: 24-0045 briefTitle: Evaluation of a Training Course for Educational Professionals overallStatus: RECRUITING date: 2024-04 date: 2025-01 date: 2025-01 date: 2024-04-26 date: 2024-04-26 name: Ludwig-Maximilians - University of Munich class: OTHER name: Prof. OTTO Beisheim Stiftung (Germany) briefSummary: The aim of this study is to evaluate the efficacy of a two-hour online training course on depression and mental health in childhood and adolescence in educational professionals to improve depression and mental health literacy. It will further be investigated whether the course leads to changes in attitudes towards the illness (reduction of stigma) and to an increased behavioural confidence and behavioral change in dealing with pupils with symptoms and illnesses. conditions: Depression conditions: Depression in Children conditions: Depression in Adolescence studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 42 type: ESTIMATED name: training course measure: increase in Knowledge measure: decrease in depression stigma measure: Change in helping behaviour towards pupil measure: Change in conficende in dealing with pupils with mental health issues measure: Evaluation of the training sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LMU University Hospital (recruitment is conducted online) status: RECRUITING city: Munich country: Germany name: Lisa Feldmann, PhD role: CONTACT email: lisa.feldmann@med.uni-muenchen.de lat: 48.13743 lon: 11.57549 hasResults: False
nctId: NCT06387095 id: 2024/01/756 briefTitle: Efficacy of Parasternal Blocks in Cardiovascular Surgery Patients Undergoing Median Sternotomy overallStatus: RECRUITING date: 2024-02-01 date: 2024-04-16 date: 2025-08-01 date: 2024-04-26 date: 2024-04-26 name: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital class: OTHER_GOV briefSummary: Acute and chronic pain after cardiac surgery is a common problem that negatively affects quality of life. Postoperative pain after cardiac surgery is most intense in the first two days and decreases in the following period. However, postoperative pain with incomplete management in the acute period may become chronic. This may negatively affect the patient's quality of life. Although central blocks such as thoracic epidural and paravertebral blocks are considered the gold standard in analgesia control, the advantages of thoracic plan blocks, which are more superficial due to peroperative heparinisation; coagulation disorders; and procedural difficulties, are undeniable. Thoracic plane blocks, which can also be used in patients receiving anticoagulant and/or antiplatelet therapy, have recently been used for acute pain. The aim of this study was to evaluate the effect of thoracic plane blocks on extubation time, pain scores, intensive care unit (ICU) and hospital stays in patients undergoing median sternotomy. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized controlled primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: 1. no block name: 2. superficial parasternal block name: 3. deep parasternal block measure: postoperative chronic pain measure: postoperative 24 hours acute pain measure: extubation time measure: icu time sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kosuyolu High Education and Training Hospital status: RECRUITING city: Istanbul state: Kartal country: Turkey name: münire deniz role: CONTACT phone: +905556461015 email: muniredeniz.md@gmail.com name: ömer savluk role: CONTACT phone: +905056877440 email: dromersavluk@hotmail.com lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06387082 id: 2023-506-00CH1 briefTitle: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-05-09 date: 2027-10-08 date: 2027-12-08 date: 2024-04-26 date: 2024-04-26 name: Hutchmed class: INDUSTRY briefSummary: This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies. Only eligible patients who provide the signed informed consent form (ICF) can be enrolled in this study. The study consists of two phases, i.e., a dose escalation phase and a dose expansion phase. The study is expected to enroll approximately 60 to 98 patients, including approximately 30 to 38 patients in the dose escalation phase and approximately 30 to 60 patients in the dose expansion phase. conditions: Hematological Malignancies studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 98 type: ESTIMATED name: HMPL-506 measure: Safety evaluation: Safety Incidence of Dose-limiting Toxicity (DLTs) measure: Safety evaluation: Incidence of serious adverse events (SAEs) and Relationship to Study Drug measure: Efficacy evaluation: Anti-tumor efficacy evaluation. measure: Incidence of adverse events (AEs) and Relationship to Study Drug measure: Adverse Events Associated with Dose Modifications measure: Evaluate electrocardiogram (ECG) assessments. measure: Complete response rate (CR rate) measure: Complete response (CR)+ Complete response with partial recovery of hematology (CRh) rate measure: Composite complete response (CRc) rate measure: Objective response rate (ORR) measure: Time to Complete response (CR)+Complete response with partial recovery of hematology (CRh) measure: Time to Complete response (CR)+Complete response with partial recovery of hematology (CRh) +incomplete hematological recovery (CRi) measure: Time to disease response (TTR) measure: Duration of Complete response (CR)+Complete response with partial recovery of hematology (CRh) measure: Duration of response (DOR) measure: Event-free survival (EFS) measure: Relapse-free survival (RFS) measure: Overall survival (OS) measure: Pharmacokinetic analysis-Maximum concentration (Cmax) measure: Pharmacokinetic analysis: Peak time (Tmax) measure: Pharmacokinetic analysis: Clearance half-life (T1/2) measure: Pharmacokinetic analysis: area under the plasma concentration-time curve (AUC0-t) measure: Evaluate the changes of the Pharmacodynamic Biomarker sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387069 id: 2023-306-00CH1 briefTitle: A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-06-03 date: 2028-06-29 date: 2024-04-26 date: 2024-04-26 name: Hutchmed class: INDUSTRY briefSummary: An open-label design is adopted in this study. All patients will first undergo pre-screening to determine the mutation status of IDH, and all patients will be assigned to the registry study of the corresponding cohorts of IDH1 and IDH2 based on the pre-screening results. Patients with both IDH1 and IDH2 mutations will be enrolled in the IDH2 cohort. This study is divided into two cohorts. Cohort 1 includes R/R AML patients with IDH1-R132 mutations; Cohort 2 includes R/R AML patients with IDH2-R140 and R172 mutations. The two cohorts are designed independently and will be analyzed separately for statistical hypothesis testing. Patients in both cohorts will be randomized in a 1:1 ratio according to the central Interactive Web Response System (IWRS) into the test or control group, patients in the test group will receive HMPL-306 monotherapy at a dose of 250 mg once daily (QD) (Cycle 1, C1) + 150 mg QD \[starting from Cycle 2 (C2)\]. Patients in the control group will receive salvage chemotherapy (one of four options) consisting of two intensive chemotherapy regimens (MEC regimen and FLAG ± Ida regimen) and two non-intensive chemotherapy regimens (azacitidine and LoDAC) conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 316 type: ESTIMATED name: HMPL-306 Regimen name: Salvage Chemotherapy Regimen measure: OS measure: CR rate measure: CR + CRh rate measure: CR + CRi + CRh rate measure: Assessments for PK (pharmacokinetics) measure: Assessments for PK (pharmacokinetics) measure: Duration of response (DOR) measure: Transfusion-dependence conversion ratio measure: HSCT(hematopoietic stem cell transplantation) ratio measure: Safety measure: Quality of life (QoL) measure: Time to response (TTR) measure: EFS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387056 id: XMYY-2024KY040 briefTitle: Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) acronym: SEGNO overallStatus: RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2029-04-01 date: 2024-04-26 date: 2024-04-26 name: The First Affiliated Hospital of Xiamen University class: OTHER briefSummary: To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer. conditions: Locally Advanced Prostate Cancer conditions: Oligometastatic Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Rezvilutamide name: Goserelin Microspheres for Injection name: Docetaxel name: Pamiparib name: Cisplatin name: Tislelizumab measure: Rate of clinical complete response (cCR) measure: Rate of pathological minimal residual disease (pMRD) measure: Rate of complete pathologic response (pCR) measure: Progression-free survival measure: Overall survival sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xiamen University status: RECRUITING city: Xiamen state: Fujian zip: 361000 country: China name: Kaiyan Zhang, M.D. role: CONTACT phone: +865922139714 email: zkyken@163.com name: Haichao Huang, M.D. role: CONTACT phone: +865922139493 email: hhc_pku@163.com lat: 24.47979 lon: 118.08187 hasResults: False
nctId: NCT06387043 id: MS and Balance briefTitle: Effects of Balance Exercises Performed With Different Visual Stimuli overallStatus: NOT_YET_RECRUITING date: 2024-12-01 date: 2025-03-01 date: 2026-12-01 date: 2024-04-26 date: 2024-04-26 name: Halic University class: OTHER name: Fenerbahce University name: Biruni University name: Istanbul University - Cerrahpasa (IUC) briefSummary: The study aims to examine the effects of balance exercises applied with different visual stimuli on individuals with MS. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Balance exercises with Virtual Reality Glasses name: Balance Exercises with Stroboscopic Glasses name: Balance Exercises with Visual-Based Metaphor Training name: Traditional Balance Exercises measure: Functional Near Infrared Ray Spectroscopy (fNIRS) measure: Timed Up and Go Test measure: Functional Reach Test measure: Berg Balance Scale measure: Timed 25 Step Walking Test measure: Lower Extremity Motor Coordination Test measure: Fatigue Severity Scale measure: Quality of Life in Multiple Sclerosis Patients sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Haliç University city: Istanbul state: Eyüpsultan country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06387030 id: APHP231662 briefTitle: EDN and Eosinophilic Esophagitis acronym: OesEDN overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-26 date: 2024-04-26 name: Assistance Publique - Hôpitaux de Paris class: OTHER name: INRAe - Micalis Institute - Jouy en Josas briefSummary: Eosinophilic esophagitis is a recent and emerging chronic disease, secondary to eosinophilic infiltration of the esophageal mucosa leading to esophageal dysfunction. The diagnosis of this pathology, and monitoring of the efficacy of therapies, relies on the assessment of eosinophilic density on esophageal biopsies: follow-up requires numerous digestive endoscopies under general anesthesia, at each therapeutic change, to assess remission. The search for non-invasive biomarkers of active eosinophilic esophagitis is therefore a subject of major interest.
The first step is to study EDN (Eosinophil-Derived Neurotoxin), a protein secreted when eosinophils are activated. Several studies have investigated the association between serum EDN, EDN on esophageal brushing or esophageal biopsies with eosinophilic esophagitis activity, and the results look promising. Urinary EDN is associated with atopy but has not been studied in eosinophilic esophagitis. EDN is a biomarker of interest because it is stable over time and, above all, can be measured routinely, making it applicable to routine patient management and care. Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies in patients undergoing upper GI endoscopy at Trousseau Hospital for suspected eosinophilic esophagitis, or as part of the re-evaluation of known eosinophilic esophagitis under treatment.
Finally, esophageal and salivary dysbiosis has been described in eosinophilic esophagitis without direct evidence of its influence on esophageal inflammation and disease. Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and/or salivary microbiota in the management of eosinophilic esophagitis.
This study will be carried out on a cohort of pediatric patients followed up in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Blood, urine, stool, saliva, 4 additional esophageal biopsies and esophageal brushings were collected on the day of the digestive endoscopy. Depending on the eosinophilic densitý on the biopsies, subjects will be classified into either the "patient with active eosinophilic esophagitis" group, the "patient with eosinophilic esophagitis in remission" group, or the "control without eosinophilic esophagitis" group. The investigator aim to include 60 patients undergoing upper GI endoscopy, at least half of whoḿ will have active or remitting eosinophilic esophagitis.
Furthermore, the study of the immunological, allergological and metabolomic signature of this disease is essential to enable the identification of new biomarkers to guide the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. In a second step, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups. In terms of clinical prospects, the investigator plan to develop a patient follow-up strategy based on the biomarkers studied, which is better adapted to clinical practice, better tolerated by patients and less costly than repeated endoscopies with esophageal biopsies. conditions: Eosinophilic Esophagitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 60 type: ESTIMATED name: Blood sampling name: Esophageal biopsies name: Unstimulated saliva sampling name: Urine sampling name: Stool sampling measure: Urinary EDN measure: Serum EDN measure: Endoluminal EDN measure: Eosinophilic infiltrate of esophagus measure: Blood eosinophilia measure: Concentrations of a panel of serum cytokines measure: Concentrations of a panel of cytokines on esophageal biopsies measure: Esophagus metabolomic profile measure: Total IgE and tryptase measure: Food or respiratory allergens sensitivity measure: Serum specific-IgE measure: Specific-IgE on esophageal biopsies measure: Composition of esophageal, salivary and fecal microbiota measure: Quality of life scale measure: Symptom score sex: ALL minimumAge: 2 Years maximumAge: 17 Years stdAges: CHILD facility: Nutrition et gastro-entérologie pédiatrique-Trousseau Hospital city: Paris zip: 75012 country: France name: Anaïs LEMOINE, Doctor role: CONTACT phone: 00 33 1 44 73 60 69 email: anais.lemoine@aphp.fr name: Patrick TOUNIAN, Professor of University role: CONTACT phone: 00 33 1 44 73 60 69 email: p.tounian@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06387017 id: RCAPHM22_0411 briefTitle: Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway acronym: BIOCEPTION overallStatus: RECRUITING date: 2024-04-02 date: 2028-07 date: 2029-07 date: 2024-04-26 date: 2024-04-26 name: Assistance Publique Hopitaux De Marseille class: OTHER briefSummary: Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation. conditions: Smoking-related Pathology conditions: Atheroma conditions: Non-progressive Cancer > 5 Years conditions: Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 750 type: ESTIMATED name: blood sampling name: stool collection name: low dose CT scan measure: biomarker group validation measure: Describe changes in biomarkers over time measure: Describe and compare biomarkers according to clinical characteristics of participants measure: Describe changes in quality of life over time measure: Describe changes in smoking habits over time measure: Describe changes in anxiety over time measure: Describe and compare biomarkers according to medical characteristics of participants measure: Describe and compare biomarkers according to geographic characteristics of participants measure: Describe and compare biomarkers according to socioeconomic characteristics of participants sex: ALL minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assistance Publique Hopitaux de Marseille status: RECRUITING city: Marseille country: France name: David Boulate role: CONTACT email: david.boulate@ap-hm.fr lat: 43.29551 lon: 5.38958 hasResults: False
nctId: NCT06387004 id: 2023-A01971-44 briefTitle: Radiation-Related Dysphagia Development Prediction Using a Two-Step Ultrasonographic Model (R-2D-2) acronym: R-2D-2 overallStatus: RECRUITING date: 2024-01-18 date: 2026-02-18 date: 2026-02-18 date: 2024-04-26 date: 2024-04-26 name: Hopital Forcilles class: OTHER briefSummary: Radiotherapy for head and neck cancers (H\&NC) heightens the risk of swallowing disorders (SD), impacting nutrition, quality of life, and overall health, leading to increased hospitalization and mortality. Dietary plans hinge on patients' nutritional status, swallowing ability, and prognosis. Early interventions are crucial, emphasizing the need for precise assessments guiding prognosis, specifying structures for intervention, and facilitating targeted rehabilitation.